NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
Clinical Trials
10 trialsNCT05025800 2026-03-20
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05467670 2026-03-04
Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer
University of Pittsburgh
Phase 2 Active not recruiting
NCT05027139 2025-10-16
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
Jazz Pharmaceuticals
Phase 1/2 Completed
NCT05002127 2025-08-07
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
ALX Oncology Inc.
Phase 2/3 Active not recruiting
NCT04675333 2025-08-03
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
ALX Oncology Inc.
Phase 2 Active not recruiting
NCT03013218 2025-08-01
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
Phase 1 Completed
NCT04675294 2025-08-01
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
ALX Oncology Inc.
Phase 2 Active not recruiting
NCT05524545 2025-07-25
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
ALX Oncology Inc.
Phase 1 Completed
NCT05787639 2025-06-25
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
University of California, San Diego
Phase 2 Recruiting